Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Obesity and diabetes

Boutari, Chrysoula, DeMarsilis, Antea, Mantzoros, Christos S. · 2023 · Diabetes Research and Clinical Practice

Abstract

Obesity, which has currently reached pandemic dimensions, is usually accompanied by diabetes mellitus type 2 (T2DM). These two conditions share common pathophysiological mechanisms. Adipose tissue secretes cytokines which are involved in inflammation and various endocrine functions. As for T2DM, it is characterized also by inflammation, mitochondrial dysfunction, and hyperinsulinemia. These conditions occur also in other diseases related to obesity and T2DM, like cardiovascular disease (CVD) and nonalcoholic fatty liver disease (NAFLD). Thus, management of obesity-related complications with lifestyle modification, anti-obesity drugs, and bariatric surgery, all contribute to improvement in any of these conditions. This review provides an overview of the literature addressing the association between obesity and T2DM, briefly discussing the pathophysiological mechanisms linking these conditions and outlining the management approach at the overlap of obesity and T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2023.110773

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 94

  1. Boutari, 2018, Inflammation: A key player linking obesity with malignancies, Metabolism, 81, A3, 10.1016/j.metabol.2017.12.015 · DOI
  2. Wei, 2022, Effects of female obesity on conception, pregnancy and the health of offspring, Front Endocrinol (Lausanne), 13
  3. Polyzos, 2019, Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics, Metabolism, 92, 82, 10.1016/j.metabol.2018.11.014 · DOI · Paper page
  4. Polyzos, 2019, Obesity: seize the day, fight the fat, Metabolism, 92, 1, 10.1016/j.metabol.2018.12.011 · DOI
  5. Boutari, 2018, Association of adipokines with development and progression of nonalcoholic fatty liver disease, Endocrinol Metab, 33, 10.3803/EnM.2018.33.1.33 · DOI · Paper page
  6. Avgerinos, 2019, Obesity and cancer risk: Emerging biological mechanisms and perspectives, Metabolism, 92, 121, 10.1016/j.metabol.2018.11.001 · DOI · Paper page
  7. Gasbarrino, 2023, Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis, Metabolism, 140
  8. Sahin-Efe, 2018, Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study, Metabolism, 79, 24, 10.1016/j.metabol.2017.10.011 · DOI
  9. Perakakis, 2021, Leptin in leanness and obesity: JACC state-of-the-art review, J Am Coll Cardiol, 77, 745, 10.1016/j.jacc.2020.11.069 · DOI · Paper page
  10. Mantzoros, 1999, The role of leptin in human obesity and disease: A review of current evidence, Ann Intern Med, 130, 671, 10.7326/0003-4819-130-8-199904200-00014 · DOI · Paper page
  11. Jung C, Kim B, Mok J, … SK-J of diabetes, 2014 undefined. Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus. Wiley Online Libr 2014;5:333–9. doi:10.1111/jdi.12144. · DOI
  12. Su, 2020, Emerging functions of adipokines in linking the development of obesity and cardiovascular diseases, Mol Biol Rep, 47, 7991, 10.1007/s11033-020-05732-9 · DOI
  13. Yadav, 2011, Correlation of adiponectin and leptin with insulin resistance: A pilot study in healthy North Indian population, Indian J Clin Biochem, 26, 193, 10.1007/s12291-011-0119-1 · DOI
  14. Muskiet, 2022, Obesity and leptin resistance in the regulation of the type I interferon early response and the increased risk for severe COVID-19, Nutrients, 14
  15. Degawa-Yamauchi, 2003, Serum resistin (FIZZ3) protein is increased in obese humans, J Clin Endocrinol Metab, 88, 5452, 10.1210/jc.2002-021808 · DOI · Paper page
  16. Yannakoulia, 2003, Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans, J Clin Endocrinol Metab, 88, 1730, 10.1210/jc.2002-021604 · DOI · Paper page
  17. Su, 2019, Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: A systematic review and meta-analysis, Front Physiol, 10
  18. Yang, 2023, Resistin impairs mitochondrial homeostasis via cyclase-associated protein 1-mediated fission, leading to obesity-induced metabolic diseases, Metabolism, 138
  19. Kawanami, 2004, Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions, Biochem Biophys Res Commun, 314, 415, 10.1016/j.bbrc.2003.12.104 · DOI · Paper page
  20. Rolph, 2002, Production of the long pentraxin PTX3 in advanced atherosclerotic plaques, Arterioscler Thromb Vasc Biol, 22
  21. Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor n.d. doi:10.1038/s42255-021-00470-z. · DOI · Paper page
  22. Dahl, 2007, Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization, Circulation, 115, 972, 10.1161/CIRCULATIONAHA.106.665893 · DOI · Paper page
  23. Takumansang R, … SW-P, 2013 undefined. Interleukin-6 and insulin resistance in obese adolescents. PaediatricaindonesianaOrg 2013;53. · doi:10.14238/pi53.5.2013.06
  24. Vityala, 2022, Evaluation of metabolic syndrome, insulin secretion and insulin resistance in adolescents with overweight and obesity, Metab - Clin Exp, 128, 10.1016/j.metabol.2021.155011 · DOI
  25. Cao, 2022, Increased plasma fatty acid clearance, not fatty acid concentration, is associated with muscle insulin resistance in people with obesity, Metabolism, 132
  26. Ye, 2011, Regulation of stem cell differentiation in adipose tissue by chronic inflammation, Clin Exp Pharmacol Physiol, 38, 872, 10.1111/j.1440-1681.2011.05596.x · DOI
  27. Endocrine JY-, Disorders-Drug M& I, 2007 undefined. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. IngentaconnectCom 2007. doi:10.2174/187153007780059423. · DOI
  28. Ye, 2013, Inflammation during obesity is not all bad: evidence from animal and human studies, Am J Physiol - Endocrinol Metab, 304, E466, 10.1152/ajpendo.00266.2012 · DOI · Paper page
  29. Weisberg S, McCann D, … MD-TJ of, 2003 undefined. Obesity is associated with macrophage accumulation in adipose tissue. Am Soc Clin Investig n.d. · DOI · Paper page
  30. Yao, 2022, Mitochondrial dysfunction in diabetic tubulopathy, Metab - Clin Exp, 131
  31. Wu Z, Puigserver P, Andersson U, Cell CZ-, 1999 undefined. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Elsevier n.d. · DOI · Paper page
  32. St-Pierre, 2003, Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells, J Biol Chem, 278, 26597, 10.1074/jbc.M301850200 · DOI · Paper page
  33. Norton, 2022, Insulin: The master regulator of glucose metabolism, Metab - Clin Exp, 129
  34. Gray S, Donald C, Jetha A, Endocrinology SC-, 2010 undefined. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic β-cell leptin signaling. AcademicOupCom n.d. · DOI
  35. Grespan, 2021, Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes, Metabolism, 114
  36. Angelidi, 2021, Novel non-invasive approaches to the treatment of obesity: From pharmacotherapy to gene therapy, Endocr Rev
  37. Ambati, 2011, GIP-dependent expression of hypothalamic genes, Physiol Res, 60, 941, 10.33549/physiolres.932151 · DOI
  38. Lakka, 2001, Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men, Atherosclerosis, 154, 497, 10.1016/S0021-9150(00)00514-1 · DOI · Paper page
  39. Liu, 2021, The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis, Metab - Clin Exp, 120
  40. Stevens, 2002, Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study, Am J Epidemiol, 156, 832, 10.1093/aje/kwf114 · DOI · Paper page
  41. Pontiroli, 2004, Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans, Eur J Endocrinol, 150, 195, 10.1530/eje.0.1500195 · DOI
  42. Kwiterovich, 2002, Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity, Am J Cardiol, 90, 30, 10.1016/S0002-9149(02)02749-2 · DOI · Paper page
  43. Howard, 2000, LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study, Arterioscler Thromb Vasc Biol, 20, 830, 10.1161/01.ATV.20.3.830 · DOI · Paper page
  44. Frénais, 2001, In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus, J Clin Endocrinol Metab, 86, 1962
  45. Smith, 2006, Free fatty acids and atherosclerosis—Guilty or innocent?, J Clin Endocrinol Metab, 91, 2506, 10.1210/jc.2006-1018 · DOI
  46. Pilz, 2006, Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease, J Clin Endocrinol Metab, 91, 2542, 10.1210/jc.2006-0195 · DOI · Paper page
  47. Rexrode, 1998, Abdominal adiposity and coronary heart disease in women, JAMA, 280, 1843, 10.1001/jama.280.21.1843 · DOI · Paper page
  48. McGavock, 2006, Adiposity of the heart, revisited, Ann Intern Med, 144, 517, 10.7326/0003-4819-144-7-200604040-00011 · DOI · Paper page
  49. Szczepaniak, 2003, Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging, Magn Reson Med, 49, 417, 10.1002/mrm.10372 · DOI · Paper page
  50. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertens (Dallas, Tex 1979) 2004;44:271–6. doi:10.1161/01.HYP.0000140058.28994.EC. · DOI · Paper page
  51. Konstantinides, 2001, Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity, J Clin Invest, 108, 1533, 10.1172/JCI13143 · DOI · Paper page
  52. Singhal, 2002, Influence of Leptin on Arterial Distensibility, Circulation, 106, 1919, 10.1161/01.CIR.0000033219.24717.52 · DOI · Paper page
  53. Alessi, 2003, Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation, Arterioscler Thromb Vasc Biol, 23, 1262, 10.1161/01.ATV.0000077401.36885.BB · DOI · Paper page
  54. haematology CE-B journal of, 2005 undefined. The interactions between inflammation and coagulation. Wiley Online Libr 2005;131:417–30. doi:10.1111/j.1365-2141.2005.05753.x. · DOI · Paper page
  55. Boutari, 2021, Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward, Metab - Clin Exp, 122
  56. Meritsi, 2022, Factors associated with hepatic steatosis in adult Greek subjects with type 2 diabetes mellitus, Metabolism, 128, 10.1016/j.metabol.2021.154968 · doi:10.1016/j.metabol.2021.154968
  57. Chung, 2021, Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea, Metabolism, 123
  58. Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis 2015. doi:10.3390/nu7115475. · DOI · Paper page
  59. endocrinology HY-J-T lancet D&, 2014 undefined. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Elsevier n.d.
  60. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013 106 2013;10:330–44. doi:10.1038/nrgastro.2013.41. · DOI · Paper page
  61. Trayhurn, 2013, Hypoxia and adipose tissue function and dysfunction in obesity, Physiol Rev, 93, 1, 10.1152/physrev.00017.2012 · DOI · Paper page
  62. Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, 1796, 10.1172/JCI200319246 · DOI · Paper page
  63. Turer, 2012, Adiponectin: Mechanistic insights and clinical implications, Diabetologia, 55, 2319, 10.1007/s00125-012-2598-x · DOI · Paper page
  64. Turer, 2012, Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study, J Clin Endocrinol Metab, 97
  65. Machado M V, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease CONCISE REVIEW 2012;11:440–9. · DOI
  66. Elsayed, 2023, 14. Children and adolescents: Standards of care in diabetes—2023, Diabetes Care, 46, S230, 10.2337/dc23-S014 · DOI · Paper page
  67. Ballesteros-Pomar, 2022, Bioelectrical impedance analysis as an alternative to dual-energy x-ray absorptiometry in the assessment of fat mass and appendicular lean mass in patients with obesity, Nutrition, 93, 10.1016/j.nut.2021.111442 · DOI
  68. Burhans, 2018, Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus, Compr Physiol, 9, 1, 10.1002/j.2040-4603.2019.tb00055.x · doi:10.1002/j.2040-4603.2019.tb00055.x · Paper page
  69. Nadolsky, 2023, American Association of Clinical Endocrinology Consensus Statement: Addressing stigma and bias in the diagnosis and management of patients with obesity/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severi, Endocr Pract, 10.1016/j.eprac.2023.03.272 · DOI · Paper page
  70. Lemos, 2017, Current body composition measurement techniques, Curr Opin Endocrinol Diabetes Obes, 24, 310, 10.1097/MED.0000000000000360 · DOI · Paper page
  71. Jensen, 2014, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, J Am Coll Cardiol, 63, 2985, 10.1016/j.jacc.2013.11.004 · DOI · Paper page
  72. Nachón, 2022, Epidemiological study on short and long-term weight loss with improvement of metabolic control in obese diabetic patients with a standardized multidisciplinary weight loss program (DIAMEX Study), Metabolism, 128, 10.1016/j.metabol.2021.155080 · doi:10.1016/j.metabol.2021.155080
  73. Salvia, 2017, The look AHEAD trial: Translating lessons learned into clinical practice and further study, Diabetes Spectr, 30, 166, 10.2337/ds17-0016 · DOI
  74. Gregg, 2012, Association of an intensive lifestyle intervention with remission of type 2 diabetes, JAMA, 308, 2489, 10.1001/jama.2012.67929 · DOI · Paper page
  75. Singh, 2019, Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials, BMJ Open, 9, e029966, 10.1136/bmjopen-2019-029966 · DOI
  76. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes | NEJM n.d. https://www.nejm.org/doi/10.1056/NEJMoa1212914?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0www.ncbi.nlm.nih.gov. · DOI · Paper page
  77. Wexler, 2022, Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trial, Obesity, 30, 1938, 10.1002/oby.23508 · DOI
  78. Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study. Obesity (Silver Spring) 2014;22:5–13. doi:10.1002/oby.20662. · DOI · Paper page
  79. Veelen, 2023, Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial, Metabolism, 140, 10.1016/j.metabol.2022.155396 · DOI
  80. DeMarsilis, 2022, Pharmacotherapy of type 2 diabetes: An update and future directions, Metabolism, 137, 10.1016/j.metabol.2022.155332 · DOI
  81. Polyzos, 2021, Diabetes mellitus: 100 years since the discovery of insulin, Metabolism, 118
  82. Billes, 2014, Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss, Pharmacol Res, 84, 1, 10.1016/j.phrs.2014.04.004 · DOI · Paper page
  83. Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), Obesity (Silver Spring), 21, 935, 10.1002/oby.20309 · DOI · Paper page
  84. Hollander, 2013, Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients, Am Diabetes Assoc
  85. Watkins, 2023, Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies, Metabolism, 140, 10.1016/j.metabol.2022.155375 · DOI
  86. le Roux, 2017, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial, Lancet, 389, 1399, 10.1016/S0140-6736(17)30069-7 · DOI · Paper page
  87. Blonde, 2009, The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies, Diabetes Obes Metab, 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
  88. Daousi, 2009, Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes, Clin Endocrinol (Oxf), 71, 195, 10.1111/j.1365-2265.2008.03451.x · DOI
  89. Fukuda, 2021, The role of GIP receptor in the CNS for the pathogenesis of obesity, Diabetes, 70, 1929, 10.2337/dbi21-0001 · DOI
  90. Healthcare, 2023, AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist, Pharm Technol
  91. Greenway, 2019, A randomized, double-blind, placebo-controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss, Obesity, 27, 205, 10.1002/oby.22347 · DOI · Paper page
  92. Rubino, 2017, Metabolic surgery in the treatment algorithm for type 2 diabetes: a Joint Statement by International Diabetes Organizations, Obes Surg, 27, 2, 10.1007/s11695-016-2457-9 · DOI · Paper page
  93. Thorell, 2012, Treatment of diabetes prior to and after bariatric surgery, J Diabetes Sci Technol, 6, 1226, 10.1177/193229681200600528 · DOI
  94. Stenberg, 2022, Guidelines for perioperative care in bariatric surgery: Enhanced recovery after surgery (ERAS) society recommendations: A 2021 update, World J Surg, 46, 729, 10.1007/s00268-021-06394-9 · DOI · Paper page

Metadata

Authors
Boutari, C., DeMarsilis, A., & Mantzoros, C. S.
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2023-08
Volume
202
Pages
110773
ISSN
0168-8227 (ISSN-L)
OpenAlex
W4381893510
Cited by
161
References
78
FWCI
26.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obesity and diabetes. https://app.cochat.ai/papers/10.1016/j.diabres.2023.110773
The paper
Boutari, C., DeMarsilis, A., & Mantzoros, C. S. (2023). Obesity and diabetes. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2023.110773

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.